Humacyte launches a public stock sale to fund Symvess commercialization and pipeline development, triggering a post-market decline.
Humacyte has initiated an underwritten public offering of its common stock, with all shares sold directly by the company. Underwriters receive a 30-day option to purchase up to 15% more shares than initially offered.
Proceeds will support the commercialization of its Symvess product, a planned Biologics License Application supplement for hemodialysis, and pipeline advancement. Funds will also cover working capital and general corporate needs.
HUMA shares fell 6% in post-market trading following the announcement.